A rifapentine double-layer suppository, preparation method and use

By designing a Rifapentin double-layer suppository, the combination of oily and water-soluble matrix is ​​used to solve the problem of poor water solubility of anti-tuberculosis drugs, the rapid release of drugs and high bioavailability are achieved, the side effects are reduced, and the treatment efficiency is improved and convenience of use.

CN115887352BActive Publication Date: 2024-11-19安康市食品药品检验检测中心(药械不良反应监测中心)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202211244807.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-12
Publication Date
2024-11-19
Estimated Expiration
2042-10-12

AI Technical Summary

Technical Problem

Existing anti-tuberculosis drugs such as rifopentin are poor in water solubility and low bioavailability, which leads to long-term treatment, multiple side effects and inconvenient use.

Method used

The two-layer suppository is used to design the upper and lower two-layer structures through the combination of oily and water-soluble matrix, and the mixture of fatty acid glycerides, glycerin gelatin and other materials are used to optimize the ratio and process to prepare the Rifopentine double-layer suppository. Achieve rapid release and rapid absorption of drugs, bypass the gastrointestinal and liver, and improve bioavailability.

Benefits of technology

It significantly improves the bioavailability of rifopentin, reduces liver and gastrointestinal stimulation, reduces side effects, shortens treatment cycle, improves treatment efficiency, and has a stable and feasible process, which is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115887352B_ABST
    Figure CN115887352B_ABST
Patent Text Reader

Abstract

The present invention discloses a rifapentine double-layer suppository, a preparation method and a use thereof. The suppository is composed of a main drug rifapentine and one or more of the auxiliary drugs rifampicin, isoniazid, ofloxacin, acyclovir, linezolid, ephedrine, ethambutol and streptomycin and a matrix. The double-layer suppository comprises an upper layer and a lower layer, wherein the lower layer is a water-soluble matrix drug-carrying layer, which allows the drug to be rapidly released and rapidly absorbed; the upper layer is a fat-soluble blank matrix, which is slowly melted to form a matrix barrier layer to effectively prevent the lower layer drug from diffusing upward, avoiding the drug from being absorbed from the upper vein through the portal hepatic system, and being absorbed from the middle and lower rectal and anal canal veins, entering the macrocirculation, improving the bioavailability of the drug, and reducing side effects. The present invention provides a rifapentine double-layer suppository and a preparation method, which has a stable process and is easy to produce. The obtained double-layer suppository has excellent quality, is fast-acting, has good efficacy and is non-irritating in the treatment of tuberculosis, solves the first-pass elimination and side effects of rifapentine, and improves the bioavailability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and relates to a double-layer suppository, a preparation method and use thereof, and specifically relates to a rifapentine double-layer suppository, a preparation method and use thereof. Background Art

[0002] Tuberculosis is a chronic, slow-onset infectious disease caused by Mycobacterium tuberculosis. The disease sites include the respiratory system, gastrointestinal digestive system, liver metabolic system and bone tissue system. Among them, respiratory system lesions mainly occur in lung tissue, trachea, bronchi and pleura. In my country, pulmonary tuberculosis is a Class B legally reportable infectious disease. Among infectious diseases, the number of cases and deaths from pulmonary tuberculosis ranks second. At present, drug treatment is the cornerstone of tuberculosis treatment. The therapeutic drugs are rifapentine, isoniazid, rifampicin, ofloxacin and prothionamide. Clinical investigations have shown that rifapentine is a long-acting antibiotic drug that kills Mycobacterium tuberculosis with a broad spectrum. It is widely used in the treatment of tuberculosis, leprosy, acute pulmonary infection and related complications, and is the most widely used. Anti-tuberculosis drugs can cause liver damage, digestive system damage, optic nerve damage and other adverse reactions. The treatment cycle for tuberculosis is long, generally one year, and some even require long-term use of anti-tuberculosis drugs. The damage caused by anti-tuberculosis drugs to liver and digestive functions is irreversible, so it is necessary to reduce this risk as much as possible.

[0003] At present, the dosage forms for treating tuberculosis include oral preparations, inhalants and perfusions, mainly oral preparations. However, oral administration often irritates the gastrointestinal tract and causes varying degrees of damage to the liver and kidneys, and the drugs are affected by gastric acid, enzymes and first-pass elimination of the liver. First-line effective drugs for treating tuberculosis, such as rifapentine, rifampicin, isoniazid and ofloxacin, are widely used. Since these drugs are insoluble in water, their application is greatly restricted. So far, there are no suppositories for clinical treatment at home and abroad, and they can only be taken orally. Because first-pass elimination greatly reduces its bioavailability and significantly increases the oral dose, it causes irreversible liver damage, digestive system damage, optic nerve damage and other side effects to patients.

[0004] Suppositories are easy to use, non-traumatic, for external use, and can provide long-term continuous administration. Rectal administration is not affected by the gastrointestinal tract, can avoid irritation and adverse reactions to the gastrointestinal tract, and avoid destruction and first-pass elimination by digestive tract enzymes. They are suitable for patients with large oral side effects and difficulties with oral administration. In addition, with the development of anatomy and other medical sciences, it has been found that suppositories exhibit good pharmacokinetic processes, and the scope of application is gradually expanding.

[0005] Therefore, it is of great significance to provide a suppository for treating tuberculosis with rapid onset, good efficacy, no irritation, few side effects and stable quality and a preparation method thereof. Summary of the invention

[0006] The purpose of the present invention is to provide a new preparation and preparation method for treating tuberculosis, which is mainly composed of rifapentine, supplemented with one or more auxiliary drugs, and is made into a double-layer suppository preparation by a modern preparation method, and is used for rectal administration, so as to improve its bioavailability, reduce side effects, shorten the treatment cycle, and be convenient to use.

[0007] The present invention achieves the above-mentioned purpose through the following technical solutions:

[0008] A rifapentine double-layer suppository, a preparation method and use thereof, which is composed of a main drug rifapentine and one or more of auxiliary drugs selected from the group consisting of rifampicin, isoniazid, ofloxacin, acyclovir, linezolid, ephedrine, ethambutol and streptomycin, and a matrix.

[0009] The main drug rifapentine in the rifapentine double-layer suppository, preparation method and use can be added with auxiliary drugs to prepare rifapentine double-layer suppositories, and the auxiliary drugs are one or more of rifampicin, isoniazid, ofloxacin, acyclovir, linezolid, ephedrine, ethambutol and streptomycin.

[0010] The rifapentine double-layer suppository, preparation method and use thereof are upper and lower double-layer suppositories with rapid release, which are composed of an oily matrix as a blank layer and a water-soluble matrix as a drug-carrying layer, and an additive. The upper layer is a blank layer, the lower layer is a drug-carrying layer, and the mass ratio of the upper and lower layers is 3-7:7-3.

[0011] Furthermore, the rifapentine double-layer suppository, preparation method and use described in the above steps are characterized in that the suppository is an upper and lower double-layer suppository, and the optimized mass ratio of the upper and lower layers is 1:2.

[0012] Furthermore, in the rifapentine double-layer suppository, preparation method and use described in the above steps, the blank layer oily matrix includes one or more of mixed fatty acid glycerides, hydrogenated vegetable oils and natural fatty acid esters; the water-soluble matrix of the drug-carrying layer includes one or more of glycerol gelatin, polyethylene glycol, polyoxyethylene stearates and poloxamer; and the additives include colorants, wetting agents, penetration enhancers, antioxidants, and agents for adjusting hardness, improving formability and stability.

[0013] Furthermore, the rifapentine double-layer suppository, preparation method and use described in the above steps is prepared from the following raw materials and auxiliary materials in parts by weight:

[0014] Blank matrix layer: 200-1000 parts of mixed fatty acid glycerides; 20-100 parts of beeswax;

[0015] Drug-containing matrix layer: PEG4000 is 200-600 parts; PEG6000 is 200-600 parts;

[0016] Drugs: The main drug is 200-800 parts of rifapentine; the auxiliary drug is 50-150 parts of ofloxacin;

[0017] Additives: 100-300 parts of glycerin; 5-10 parts of lauryl azone; 1-3 parts of carmine.

[0018] Furthermore, the rifapentine double-layer suppository, preparation method and use described in the above steps is prepared from the following raw materials and excipients in optimized weight portions:

[0019] Blank matrix layer: 490 parts of mixed fatty acid glycerides; 50 parts of beeswax;

[0020] Drug-containing matrix layer: PEG4000 is 280 parts; PEG6000 is 280 parts;

[0021] Drugs: The main drug is 300 parts of rifapentine; the auxiliary drug is 75 parts of ofloxacin;

[0022] Additives: 140 parts of glycerin; 5.5 parts of laurocapram; 2 parts of carmine;

[0023] 1000 tablets are prepared, each tablet containing 0.3 parts of rifapentine and 0.075 parts of ofloxacin.

[0024] Furthermore, the rifapentine double-layer suppository, preparation method and use described in the above steps is prepared by the following steps:

[0025] (1) Weigh the mixed fatty acid glyceride and beeswax according to the prescription ratio, heat and melt at a temperature of 55-65°C, mix evenly, and inject into a mold. The injection volume accounts for one-third of the total volume. Condensate and set aside at a condensation temperature of 5-15°C as a blank matrix layer; (2) Calculate the replacement price and weigh PEG4000, PEG6000, glycerin, laurocapram, carmine, rifapentine and ofloxacin according to the prescription ratio. First, heat and melt PEG4000, PEG6000, glycerin and laurocapram at a temperature of 60-70°C, mix evenly, and keep warm for use;

[0026] (3) The matrix prepared in step (2) is divided into 5 to 10 equal parts in increasing amounts, and is slowly added to carmine, rifapentine and ofloxacin in small amounts and multiple times under stirring, and is continuously stirred to mix evenly to form a drug-containing matrix layer, which is kept warm at 60 to 70° C. for later use;

[0027] (4) After the blank matrix layer prepared in step (1) is condensed, the drug-containing matrix layer prepared in step (3) is preheated to 75-85° C. and poured onto the blank matrix layer until it is full. After condensation at a temperature of 5-15° C., the drug-containing matrix layer is scraped and removed from the membrane to obtain the blank matrix layer.

[0028] The present invention also provides the above-mentioned rifapentine double-layer suppository, a preparation method and use thereof, which is used for the treatment of tuberculosis, leprosy, acute pulmonary infection and related complications.

[0029] Compared with the prior art, the present invention has the following advantages:

[0030] 1. We have broken through the limitation that rifapentine, isoniazid, linezolid, rifampicin and other first-line drugs for the treatment of tuberculosis are only for oral use. We have developed a new dosage form of rifapentine double-layer suppository and a preparation method suitable for industry, providing a new drug dosage form for the treatment of modern tuberculosis;

[0031] 2. The rifapentine double-layer suppository developed by the present invention consists of an upper layer and a lower layer. Through the screening and proportioning of different matrices, the drug can be rapidly released and absorbed. At the same time, the drug can bypass the gastrointestinal tract and liver and enter the macrocirculation, thereby increasing the bioavailability of the drug and reducing toxic side effects. It effectively avoids gastrointestinal irritation and the first-pass effect of the liver, and is not damaged by pH and enzymes, thus reducing the occurrence of adverse reactions;

[0032] 3. The rifapentine double-layer suppository developed by the present invention has rifapentine as the main drug, and other related therapeutic drugs can be added according to clinical treatment needs. Through replacement price calculation, the main drug is added to the lower drug-loading matrix layer of the double-layer suppository to prepare a double-layer suppository preparation, so as to achieve the use of drugs in combination and improve clinical efficacy;

[0033] 4. The preparation process of the rifapentine double-layer suppository provided by the present invention is stable and feasible, easy to produce and operate, and the prepared double-layer suppository is of excellent quality. It has a rapid onset of action, good efficacy, and is non-irritating in the clinical treatment of tuberculosis, and solves the first-pass elimination effect and toxic side effects of rifapentine drugs;

[0034] 5. In vitro dissolution tests showed that the dissolution rate and extent of rifapentine double-layer suppositories were better than those of existing rifapentine capsules;

[0035] 6. Bioequivalence tests showed that the bioavailability of rifapentine double-layer suppositories was nearly twice that of the reference preparation, rifapentine capsules, which greatly improved the bioavailability of rifapentine. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The present invention is a schematic diagram of a dosage form of a rifapentine double-layer suppository, a preparation method and a use thereof.

[0037] Figure 2Figure 1 is the structural diagram of rifapentine.

[0038] Figure 3 This is the structure diagram of ofloxacin.

[0039] Figure 4 The results of dissolution comparison of two rifapentine preparations are shown in Figure 2. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail in conjunction with the following examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In view of the problems existing in the prior art, the present invention provides a rifapentine double-layer suppository, a preparation method and use, and the present invention is described in detail in conjunction with the following examples.

[0041] The sources of the raw and auxiliary materials used in the embodiments of the present invention are as follows:

[0042] The main drug is rifapentine, which is included in the national drug standard WS1-(X-305)-2004Z (raw material). It is a new generation of long-acting rifamycin antibiotics. Its chemical name is 3-[[(4-cyclopentyl-1-piperazinyl)imino]methyl]-rifamycin, and its molecular formula is C 47 H 64 N4O 12 , molecular weight is 877.04. Calculated on a dry basis, it contains C 47 H 64 N4O 12 Not less than 97.0%. Chemical structure Figure 2 .

[0043] The auxiliary drugs are one or more of rifampicin, isoniazid, ofloxacin, acyclovir, linezolid, ephedrine, ethambutol and streptomycin, all of which are included in Part II of the 2020 edition of the "Chinese Pharmacopoeia"; glycerin, laurocapram, beeswax and carmine are of pharmaceutical grade.

[0044] Ofloxacin is a broad-spectrum antibacterial fluoroquinolone drug. Its chemical name is (±)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, and its molecular formula is C 18 H 20 FN3O4, molecular weight is 361.37. Calculated on a dry basis, it contains C 18 H 20 FN3O4 shall not be less than 97.5%. Chemical structure see Figure 3 .

[0045] Example 1 Preparation of a Rifapentine Double-layer Suppository

[0046] (1) Prescription

[0047] Blank matrix layer: 490g mixed fatty acid glycerides; 50g beeswax

[0048] Drug-containing matrix layer: PEG4000 is 280g; PEG6000 is 280g

[0049] Drugs: The main drug is rifapentine 300g; the auxiliary drug is isoniazid 75g

[0050] Additives: glycerin 140g; laurocapram 5.5g; carmine 2g

[0051] Made into 1000 tablets, each weighing 1.62g, each containing 0.3g of rifapentine and 0.075g of isoniazid

[0052] (2) Preparation method

[0053] Weigh the above raw materials and excipients according to the prescription ratio, first heat and melt the blank layer matrix mixed with fatty acid glyceride and beeswax, the heating temperature is 60°C, mix evenly, inject into the mold, 0.54g per hole, condense for use, the condensation temperature is 10°C, as the blank matrix layer. Then heat and melt the drug-carrying layer matrix PEG4000, PEG6000, glycerol and lauryl azone, the heating temperature is 65°C, mix evenly, and keep warm for use. Then divide the prepared drug-carrying layer matrix into 7 parts in equal increments, slowly add carmine, rifapentine and isoniazid in a stirring state, a small amount multiple times, constantly stir, mix evenly, as the drug-containing matrix layer, keep warm for use at a temperature of 65°C. After the prepared blank matrix layer is condensed, preheat the prepared drug-containing matrix layer to 80°C, inject into the mold, 1.08g per hole, condense at a temperature of 10°C, scrape, demold and take out.

[0054] Example 2 Preparation of a Rifapentine Double-layer Suppository

[0055] (1) Prescription

[0056] Blank matrix layer: 490g mixed fatty acid glycerides; 50g beeswax

[0057] Drug-containing matrix layer: PEG4000 is 280g; PEG6000 is 280g

[0058] Drugs: The main drug is rifapentine 300g; the auxiliary drug is ofloxacin 75g

[0059] Additives: glycerin 140g; laurocapram 5.5g; carmine 2g

[0060] Made into 1000 tablets, each weighing 1.62g, each containing 0.3g of rifapentine and 0.075g ofloxacin

[0061] (2) Preparation method

[0062] Weigh the above raw materials and excipients according to the prescription ratio, first heat and melt the blank layer matrix, mix fatty acid glyceride and beeswax, the heating temperature is 60°C, mix evenly, inject into the mold, 0.54g per hole, condense for use, the condensation temperature is 10°C, as the blank matrix layer. Then heat and melt the drug-carrying layer matrix PEG4000, PEG6000, glycerol and lauryl azone, the heating temperature is 65°C, mix evenly, and keep warm for use. Then divide the prepared drug-carrying layer matrix into 7 parts in equal increments, slowly add carmine, rifapentine and ofloxacin in a small amount and multiple times under stirring, stir constantly, mix evenly, as the drug-containing matrix layer, keep warm for use at a temperature of 65°C. After the prepared blank matrix layer is condensed, preheat the prepared drug-containing matrix layer to 80°C, inject into the mold, 1.08g per hole, condense at a temperature of 10°C, scrape, demold and take out, and you are done.

[0063] Example 3 Preparation of a Rifapentine Double-layer Suppository

[0064] (1) Prescription

[0065] Blank matrix layer: mixed fatty acid glyceride 410g; beeswax 40g

[0066] Drug-containing matrix layer: PEG4000 is 240g; PEG6000 is 240g

[0067] Drug: The main drug is rifapentine 300g

[0068] Additives: glycerin 120g; laurocapram 5.0g; carmine 2g

[0069] Made into 1000 tablets, each weighing 1.35g, each containing 0.3g of rifapentine

[0070] (2) Preparation method

[0071] Weigh the above raw materials and excipients according to the prescription ratio, first heat and melt the blank layer matrix, mix fatty acid glyceride and beeswax, the heating temperature is 60°C, mix evenly, inject into the mold, 0.45g per hole, condense for use, the condensation temperature is 10°C, as the blank matrix layer. Then heat and melt the drug-carrying layer matrix PEG4000, PEG6000, glycerol and lauryl azone, the heating temperature is 65°C, mix evenly, and keep warm for use. Then divide the prepared drug-carrying layer matrix into 7 parts in equal increments, slowly add carmine and rifapentine in a small amount and multiple times under stirring, stir constantly, mix evenly, as the drug-containing matrix layer, keep warm for use at a temperature of 65°C. After the prepared blank matrix layer is condensed, preheat the prepared drug-containing matrix layer to 80°C, inject into the mold, 0.90g per hole, condense at a temperature of 10°C, scrape, demold and take out, and you are done.

[0072] The beneficial effects of the present invention are described below through specific examples.

[0073] Example 1 Quality Study of a Rifapentine Double-layer Suppository in the Present Application

[0074] 1. Selection of evaluation indicators

[0075] The comprehensive score (Q) is based on the appearance of the double-layer plug (Q1), weight difference (Q2), melting time (Q3) and the firmness of the two-layer joint (Q4). A 1-3 point evaluation standard is established, Q = Q1 + Q2 + Q3 + Q4. The specific scoring details are as follows:

[0076] (1) Appearance (Q1) Take 10 suppositories prepared in the examples. Observe them separately. The appearance should be complete and smooth, uniform in color, without bubbles, and have appropriate hardness. The hardness is measured using the tablet hardness measurement method. Scoring criteria: 0 points for no shape or bubbles, 1 point for rough shape and no bubbles, 2 points for relatively rough shape and no bubbles, 3 points for smooth shape and no bubbles; the optimal hardness range is 10-12N, <4N or >15N is 0 point, 4-10N or 12-15N is 1 point, and 10-12N is 3 points;

[0077] (2) Weight difference (Q2) Referring to the 2020 edition of the Chinese Pharmacopoeia, Part IV, General Rules for Preparations, 0107 Suppositories, take 10 suppositories prepared in the following examples, accurately weigh the total weight, calculate the average particle weight, and then accurately weigh each particle to calculate the weight difference limit. Scoring criteria: weight difference limit > 10% is 0 points, 5-10% is 1 point, and < 5% is 3 points;

[0078] (3) Melting time limit (Q3) Refer to the melting time limit inspection method in Part IV of the 2020 edition of the Chinese Pharmacopoeia 0922. Take 3 suppositories prepared in the example, place them at room temperature for 1 hour, place them on the lower circular plates of 3 metal racks, put them into their respective sleeves, and fix them with hooks. Unless otherwise specified, the above devices are vertically immersed in containers containing no less than 4L of 37.0±0.5℃ water, and the upper end should be 90mm below the water surface. A rotator is installed in the container to flip the device in the solution every 10 minutes. All 3 suppositories should be completely melted, softened or have no hard core when touched within 30 minutes. Scoring criteria: 0 points for no melting, 1 point for 30-60 minutes, and 3 points for ≦30 minutes;

[0079] (4) Firmness of the joint between the two layers (Q4) Take 10 suppositories prepared in the examples, fix the double-layer suppositories on an iron stand with the blank layer facing downward, use a treated bamboo stick to pierce the blank layer horizontally, and attach the two ends of the toothpick with the two ends of a thin line, and fix a weight on the thin line. The weight of the weight represents the firmness of the joint between the drug-containing layer and the blank layer. The result is expressed in Newton (1g = 0.0098N). Scoring criteria: <1.00N is 0 points, 1-2.00N is 1 point, and >2.00N is 3 points;

[0080] (5) Dissolution was determined according to the dissolution and release test method in Part IV of the 2020 edition of the Chinese Pharmacopoeia (Chinese Pharmacopoeia). A pH of 7.4 phosphate buffer solution was selected as the dissolution medium, and the rotation speed was 100 r / min. -1 The water bath temperature was 37.0±0.5℃. The dissolution of rifapentine double-layer suppositories was determined by taking 5 mL at 5, 10, 15, 20, 30, 40 and 50 min, and adding an equal volume of isothermal dissolution medium. The entire test process must be protected from light;

[0081] Chromatographic conditions: Shimadzu LC-20AT high performance liquid chromatograph, LC Solution chromatography workstation; octylsilane bonded silica gel as filler; methanol-acetonitrile-0.075 mol·L -1 Potassium dihydrogen phosphate solution - 1.0 mol·L -1 Citric acid solution (30:30:37:3) was used as the mobile phase; the flow rate was 1.0 mL.min -1 ; Column temperature was 35°C; Detection wavelength was 254nm;

[0082] Preparation of the test solution: Accurately measure 2 mL of each of the 5 mL of the dissolution solution obtained in step (5) above, place in a 10 mL volumetric flask, dilute to scale with the mobile phase, shake well, filter through a 0.45 μm microporous filter membrane, and take the filtrate to obtain;

[0083] Preparation of reference solution Take an appropriate amount of rifapentine reference solution, weigh accurately, place in a volumetric flask, and prepare with mobile phase to a concentration of about 10 μg.mL -1 Prepare the reference solution for later use.

[0084] 2. Matrix type screening

[0085] Rifapentine is a water-insoluble drug, so a water-soluble matrix is ​​selected for the lower drug-carrying layer, which can rapidly release and absorb the drug. A fat-soluble matrix can be selected for the upper blank layer, which is slowly melted to form a matrix barrier layer that effectively prevents the lower layer drug from diffusing upward, avoiding a considerable portion of rifapentine from being absorbed through the portal hepatic system from the superior vein, and directly bypassing the liver from the middle and inferior rectal veins and anal canal veins to enter the general circulation, thereby improving the bioavailability of rifapentine and reducing toxic side effects. Commonly used fat-soluble matrices include mixed fatty acid glycerides, hydrogenated vegetable oils, and natural fatty acid esters. Commonly used water-soluble matrices include glycerin gelatin, polyethylene glycol, polyoxyethylene stearates, and poloxamer. The test screened the matrix types using the comprehensive score as the evaluation index, and the results are shown in Table 1:

[0086] Table 1 Comprehensive score results of matrix type screening

[0087]

[0088] The results showed that the mixed fatty acid glycerides and beeswax were selected as the blank matrix layer; the polyethylene glycol mixture and glycerol were selected as the drug-loaded matrix layer. The comprehensive scores were high and suitable for the preparation of double-layer suppositories.

[0089] 3. Investigation of matrix ratio

[0090] On the basis of matrix type screening, the test used the comprehensive score as the evaluation index to select the matrix ratio. The results are shown in Table 2:

[0091] Table 2 Comprehensive score results of matrix and matrix ratio investigation

[0092]

[0093] The results showed that the blank matrix layer mixed fatty acid glyceride and beeswax in a ratio of 10:1; the drug-loaded matrix layer PEG4000, PEG6000, glycerol in a ratio of 2:2:1, the comprehensive score was higher. When beeswax was added to the blank matrix layer, the formability of the suppository was significantly improved, the demoulding cooling time was shortened, and it was helpful to improve the formability of the double-layer suppository and the firmness of the two-layer joint. When glycerol was added to the drug-loaded matrix layer, it not only increased the lubricity of the suppository and reduced the irritation of polyethylene glycol, but also increased the dissolution rate of the suppository and made the drug dissolve quickly. At the same time, glycerol has a certain moisturizing effect, which can prevent the suppository from drying and hardening during storage.

[0094] 4. Injection mold temperature inspection

[0095] On the basis of the determination of the matrix type and matrix ratio, the test was conducted on different injection molding temperatures using various evaluation indicators. The results are shown in Table 3:

[0096] Table 3 Results of investigation on different injection molding temperatures

[0097]

[0098] The results show that the injection molding temperature directly affects the quality of the finished double-layer suppository. If the temperature is too low, the fluidity is poor and the mixing is uneven. If the temperature is too high, the cooling time will increase, making the drug easy to settle. If the preheating temperature of the drug-loaded matrix layer in the secondary injection molding is too low, it is easy to produce faults. If the temperature is too high, it will affect the stability of the drug and increase the cooling time, which is not conducive to the molding of the double-layer suppository. When the temperature of the blank matrix is ​​60℃, it is easy for the blank layer to be molded; when the temperature of the drug-loaded matrix is ​​65℃, it is easy for the drug to be mixed evenly and the drug-loaded matrix layer to be molded; when the preheating temperature of the drug-loaded matrix layer is 80℃, it is easy for the double-layer suppository to be molded, it is not easy to produce faults, and the two layers have good firmness. When the cooling temperature is 10℃, the cooling time is appropriate and it is not easy to produce cracks due to sudden cooling.

[0099] 5. Process verification

[0100] (1) The mass ratio of the upper and lower layers of the prescription was 1:2. The mass of each raw material and auxiliary material was weighed according to the replacement price calculation as follows: Blank matrix layer: 410 g of mixed fatty acid glyceride; 40 g of beeswax

[0101] Drug-containing matrix layer: PEG4000 is 240g; PEG6000 is 240g

[0102] Drug: The main drug is rifapentine 300g

[0103] Additives: glycerin 120g; laurocapram 5.0g; carmine 2g

[0104] Made into 1000 tablets, each weighing 1.35g, each containing 0.3g of rifapentine

[0105] (2) The method was validated in three batches according to the above-mentioned optimal conditions.

[0106] Weigh the above raw materials and excipients according to the prescription ratio, first heat and melt the blank layer matrix, mix fatty acid glyceride and beeswax, the heating temperature is 60°C, mix evenly, inject into the mold, 0.45g per hole, condense for use, the condensation temperature is 10°C, as the blank matrix layer. Then heat and melt the drug-carrying layer matrix PEG4000, PEG6000, glycerol and lauryl azone, the heating temperature is 65°C, mix evenly, and keep warm for use. Then divide the prepared drug-carrying layer matrix into 7 parts in equal increments, slowly add carmine and rifapentine in small amounts and multiple times under stirring, stir constantly, mix evenly, as the drug-containing matrix layer, keep warm for use at a temperature of 65°C. After the prepared blank matrix layer is condensed, preheat the prepared drug-containing matrix layer to 80°C, inject into the mold, 0.90g per hole, condense at a temperature of 10°C, scrape, demold and take out. The three batches of double-layer plugs were inspected for appearance, weight difference, melting time and firmness of the two-layer joint according to the scoring criteria of the evaluation indexes. The results are shown in Table 4:

[0107] Table 4 Scoring results of different evaluation indicators for process validation

[0108]

[0109] The experimental results show that the three batches of double-layer suppositories prepared are all complete and smooth in appearance, with appropriate hardness, the firmness of the two-layer joint is reliable, and the weight difference and melting time limit meet the requirements of the suppositories under the general rules of the fourth volume of the Chinese Pharmacopoeia in 2022. The invention process is stable and feasible, simple to operate, and has good repeatability.

[0110] 6. Comparative ratio

[0111] Three batches of rifapentine double-layer suppositories in the process verification example of this application and three batches of rifapentine capsules purchased from the market (National Medicine Standard No. H10940211, Sichuan Changzheng Pharmaceutical Co., Ltd.) were respectively taken and compared with each other according to the preferred dissolution determination method in the above evaluation index (5). The results are shown in Table 1. Figure 4 :

[0112] The results show that the cumulative dissolution amount of the rifapentine double-layer suppository developed in the present application is slightly better than that of the commercially available rifapentine capsule in the same period of time. This is because rifapentine is highly dispersed in the suppository, and glycerol has a solubilizing and wetting effect in the polyethylene glycol matrix, so its dissolution rate in the suppository is faster.

[0113] Example 2 Bioequivalence test of a rifapentine double-layer suppository of the present application

[0114] Six healthy male Beagle dogs weighing 8.0±1.0kg were selected, and a two-preparation single-dose double-period crossover experimental design was adopted. The six male Beagle dogs were randomly divided into two groups, A and B, with 3 dogs in each group, wherein Group A was given the rifapentine double-layer suppository test preparation under the embodiment of the present application, rectally administered, with a dose of one suppository each time, 0.3g / suppository. Group B was given the reference preparation Fupentine Capsules (National Medicine Standard H10940211, Sichuan Changzheng Pharmaceutical Co., Ltd., 150mg / capsule), intragastrically administered, with a dose of 4 capsules each time, and then a crossover test was conducted, with an interval of two weeks between the two administrations. Fast overnight (more than 12 hours) before administration. On the next morning, when fasting (0 hours before administration), and after eating (water), 2 mL of blood was collected from the saphenous vein of the forelimbs using ethylenediaminetetraacetic acid (EDTA) anticoagulant tubes at 2, 4, 5, 6, 8, 12, 24, and 72 hours after administration according to the requirements of each preparation. The blood was centrifuged at 3000 r / min for 10 minutes, and the plasma was stored at -20°C for the test preparation and reference preparation.

[0115] Chromatographic and mass spectrometric conditions Waters ACQUITY UPLC TM Ultra-high pressure liquid chromatography; Agilent SB-Aq column (1.8 μm, 100 mm × 2.1 mm); mobile phase A: 15 nmol / L ammonium formate, mobile phase B: methanol; gradient elution: 0-2 min, 5→30 B%; 2-7 min, 30→95 B%; 7-9 min, 95 B%; 9-12 min, 95→5 B%; detection wavelength 254 nm, flow rate 0.5 mL / min, column temperature 40 °C, injection volume 5 μL. Waters SYNAPT G2-S Q-TOF mass spectrometer, electrospray ionization source (ESI), positive ion mode, curtain gas and auxiliary gas 1 and auxiliary gas 2 are all nitrogen, their pressures are all 45 PSI, ion source voltage 5000 V, ion source temperature 550 °C. Multiple reaction monitoring (MRM) was used for quantitative analysis of the compounds;

[0116] Precisely pipette 0.10-0.20 mL of plasma into a 2 mL EP tube, accurately add 0.1 mL of internal standard (rifampicin), then accurately add 0.80 mL of acetonitrile, vortex for 5 min, and incubate at 4 °C, 12000 r / min -1 Centrifuge for 10 minutes. Carefully aspirate 0.50 mL of the supernatant, blow dry with nitrogen, add 0.2 mL of mobile phase to the residue, vortex for 5 minutes, and incubate at 4°C, 12,000 r / min. -1 Centrifuge for 10 minutes, take the supernatant and set aside. The entire test process must be protected from light;

[0117] Data processing DAS2.0 software (Shanghai Bojia Pharmaceutical Technology Co., Ltd.) was used to analyze the blood concentration data of rifapentine to obtain non-compartmental pharmacokinetic parameters, including the area under the blood concentration-time curve [AUC (0~t) and AUC (0~∞) ], half-life (t 1 / 2 ), peak time (t max ), and peak plasma concentration (C max ) and analyzed. Relative bioavailability (F) = AUC 受试制剂 / AUC 参比制剂 , the results are shown in Table 5:

[0118] Table 5 Results of bioequivalence determination of rifapentine preparations

[0119]

[0120] The results showed that the bioavailability of the applied rifapentine double-layer suppository at a single dose of 0.3g was equivalent to the bioavailability of the reference preparation rifapentine capsule at a single dose of 0.6g, which greatly reduced the amount of rifampicin used and improved the bioavailability of rifapentine.

[0121] Safety evaluation showed that blood pressure, electrocardiogram, blood routine and blood biochemical tests before and after administration were all within the normal range, and no adverse drug reactions were found.

Claims

1. A rifapentine double-layer suppository, It is characterized in that The suppository is composed of the main drug rifapentine and one or more of the auxiliary drugs rifampicin, isoniazid, ofloxacin, acyclovir, linezolid, ephedrine, ethambutol and streptomycin, and a matrix; The suppository is an upper and lower double-layer suppository rapid-release preparation, which is composed of an oily matrix as a blank layer and a rapid-release water-soluble matrix as a drug-loaded layer, the upper layer is a blank layer, the lower layer is a drug-loaded layer, and the mass ratio of the upper and lower layers is 3-7:7-3; The blank layer oily matrix includes mixed fatty acid glyceride and beeswax, and the drug-carrying layer water-soluble matrix includes PEG4000, PEG6000 and glycerol.

2. A rifapentine double-layer suppository as claimed in claim 1, It is characterized in that The rifapentine double-layer suppository is prepared from the following raw materials and auxiliary materials in parts by weight: Blank matrix layer: 200-1000 parts of mixed fatty acid glycerides; 20-100 parts of beeswax; Drug-containing matrix layer: PEG4000 is 200-600 parts; PEG6000 is 200-600 parts; The main drug is 200-800 parts of rifapentine; the auxiliary drug is 50-150 parts of ofloxacin; 100-300 parts of glycerin; 5-10 parts of laurocapram; 1-3 parts of carmine.

3. A rifapentine double-layer suppository according to any one of claims 1 to 2, It is characterized in that The upper and lower layers have a mass ratio of 1:2; they are prepared from the following raw materials and auxiliary materials in parts by weight: Blank matrix layer: 490 parts of mixed fatty acid glycerides; 50 parts of beeswax; Drug-containing matrix layer: PEG4000 is 280 parts; PEG6000 is 280 parts; The main drug is 300 portions of rifapentine; The auxiliary drug is 75 parts of ofloxacin; 140 parts of glycerin; 5.5 parts of laurocapram; 2 parts of carmine; 1000 tablets are prepared, each tablet containing 0.3 parts of rifapentine and 0.075 parts of ofloxacin.

4. A method for preparing a rifapentine double-layer suppository according to any one of claims 1 to 3, It is characterized in that It is prepared by the following steps: (1) Weigh the mixed fatty acid glyceride and beeswax according to the prescription ratio, heat to melt, the heating temperature is 55-65°C, mix evenly, inject into a mold, inject 0.54g, condense for use, the condensation temperature is 5-15°C, as a blank matrix layer; (2) Calculate the replacement price and weigh PEG4000, PEG6000, glycerin, laurocapram, carmine, rifapentine and ofloxacin according to the prescription ratio. First, heat PEG4000, PEG6000, glycerin and laurocapram to melt at 60-70° C., mix them evenly, and keep them warm for later use; (3) The matrix prepared in step (2) is divided into 5 to 10 equal parts in increasing amounts, and is slowly added to carmine, rifapentine and ofloxacin in small amounts and multiple times under stirring, and is continuously stirred to mix evenly to form a drug-containing matrix layer, which is kept warm at 60 to 70° C. for later use; (4) After the blank matrix layer prepared in step (1) is condensed, the drug-containing matrix layer prepared in step (3) is preheated to 75-85° C. and poured onto the blank matrix layer until it is full. After condensation at a temperature of 5-15° C., the drug-containing matrix layer is scraped, removed from the membrane, and the blank matrix layer is obtained.

5. Use of the rifapentine double-layer suppository according to any one of claims 1 to 3 in the preparation of medicines for treating tuberculosis, leprosy or acute lung infection.

Citation Information

Patent Citations

  • Rifaximin double-layered gel suppository for animals and preparation method thereof

    CN106902074A

  • Composition for treating tuberculosis

    RU2185168C1

  • Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions

    US20030064097A1

  • Medicament capsules for rectal application

    US4402692A